| |
Controls (n = 26)
|
Oral N-BP (n = 30)
|
i.v. N-BP* (n = 31)
|
ONJ (n = 6)
|
p value
|
|---|
|
Cytokines
|
|
RANK
a
|
0.95 ± 0.09
|
0.95 ± 0.03
|
0.94 ± 0.06
|
1.0 ± 0.13*
|
0.026
|
|
RANKL
a
|
1.0 ± 0.08
|
0.98 ± 0.04^
|
0.97 ± 0.05^^
|
1.1 ± 0.1
|
0.007
|
|
TNFA
|
8.1 ± 1.4
|
7.6 ± 1.3
|
7.5 ± 1.8
|
10.2 ± 1.7
|
0.001
|
|
IL17
|
12.6 ± 1.6
|
13.4 ± 0.97
|
12.8 ± 1.1
|
13.3 ± 3.0
|
0.129
|
|
IFNG
|
13.8 ± 4.5
|
14.8 ± 3.9
|
15.5 ± 3.0
|
11.9 ± 1.3
|
0.109
|
|
IL1B
|
10.8 ± 1.4
|
10.7 ± 1.1
|
10.7 ± 0.96
|
10.5 ± 1.1
|
0.942
|
|
Growth and wound healing factors
|
|
FGF9
|
11.3 ± 1.8
|
10.7 ± 0.8
|
10.1 ± 1.1***
|
12.9 ± 0.9*
|
<0.001
|
|
GMCSF
|
14.7 ± 1.6
|
14.2 ± 1.1
|
14.0 ± 1.3
|
16.4 ± 1.7*
|
0.001
|
|
CTGF
a
|
0.86 ± 0.14
|
0.79 ± 0.10
|
0.80 ± 0.11
|
0.93 ± 0.14
|
0.013
|
|
MMP7
a
|
0.86 ± 0.08
|
0.85 ± 0.05
|
0.84 ± 0.08^
|
0.93 ± 0.16
|
0.040
|
|
MMP9
a
|
0.96 ± 0.07
|
0.95 ± 0.10
|
0.96 ± 0.09
|
0.92 ± 0.10
|
0.611
|
|
Response to challenge (endogenous or exogenous)
|
|
AHR
2
|
0.93 ± 0.06
|
0.90 ± 0.03
|
0.89 ± 0.05*
|
1.0 ± 0.10**
|
<0.001
|
- ΔCt values decrease with increased gene expression; lower values correspond to greater gene expression and higher values to lower gene expression.
- Tukey HSD post hoc test: * significantly different from controls, p < 0.05; ** significantly different from controls, p < 0.01; *** significantly different from controls, p < 0.005; ^ significantly different from ONJ, p < 0.05; ^^ significantly different from ONJ, p < 0.01. The differences between the N-BP treatment groups and ONJ are only shown for factors where there was no significant difference with the control group. The greatest differences were observed between N-BP treated groups without a history of ONJ and those with ONJ.
-
i.v. intravenous.
-
aData are log10 transformed.
